Почетна › Кронова болест › Северна Каролина
Клинички испитувања за Кронова болест во Северна Каролина
20 студии за Кронова болест бараат учесници на локации во Северна Каролина.
Градови во Северна Каролина
Официјален текст на студијата (англиски)
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Digestive Health Partners /ID# 280490, Asheville
Се регрутираФаза 2
Возраст од 18 до 75 · Сите полови · Ажурирано 5.10.2026 · NCT07697456A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically
- University of North Carolina at Chapel Hill, Chapel Hill
Се регрутираФаза 4
Возраст 18 и постари · Жени · Ажурирано 5.10.2026 · NCT07654751A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- University of North Carolina Medical Center ( Site 5034), Chapel Hill
- Atrium Health Gastroenterology MMP ( Site 5105), Charlotte
Се регрутираФаза 3
Возраст од 16 до 80 · Сите полови · Ажурирано 2.10.2026 · NCT06430801A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Charlotte Gastroenterology and Hepatology, P.L.L.C, Charlotte
- Carolina Digestive Diseases, Greenville
- Piedmont Healthcare, Statesville
- и уште 1
Се регрутираФаза 4
Возраст од 18 до 80 · Сите полови · Ажурирано 30.9.2026 · NCT06581328Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Digestive Health Partners - Biltmore Office /ID# 265539, Asheville
Се регрутираФаза 2
Возраст од 18 до 75 · Сите полови · Ажурирано 25.9.2026 · NCT06548542A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- University of North Carolina at Chapel Hill, Chapel Hill
- Charlotte Gastroenterology and Hepatology, PLLC, Charlotte
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT07499232A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- University of North Carolina, Chapel Hill
- Atrium Health, Charlotte
Се регрутираФаза 2/3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT07196722Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Coastal Research Institute - Fayetteville, Fayetteville
Се регрутираФаза 3
Возраст од 18 до 70 · Сите полови · Ажурирано 24.9.2026 · NCT06937099An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- UNC Hospitals, The University of North Carolina at Chapel Hill-Site Number: 8400074, Chapel Hill
- OnSite Clinical Solutions-Site Number: 8400051, Charlotte
- Duke University Medical Center-Site Number: 8400093, Durham
- и уште 3
Се регрутираФаза 3
Возраст од 16 до 80 · Сите полови · Ажурирано 23.9.2026 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- UNC Hospitals, The University of North Carolina at Chapel Hill-Site Number: 8400074, Chapel Hill
- Cross Creek Medical Clinic-Site Number: 8400057, Fayetteville
Се регрутираФаза 3
Возраст од 16 до 80 · Сите полови · Ажурирано 23.9.2026 · NCT07184944A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- Cross Creek Medical Clinic, Fayetteville
- Peters Medical Research, High Point
- Wake Research Associates, Raleigh
Се регрутираФаза 2
Возраст од 18 до 85 · Сите полови · Ажурирано 22.9.2026 · NCT06226883A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- University of North Carolina Hospital, Chapel Hill
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 28.8.2026 · NCT07577843Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- University of North Carolina, Chapel Hill
- Atrium Health Center for Gastroenterology and Surgery, Charlotte
- Wake Forest School of Medicine, Winston-Salem
Се регрутираНабљудувачка студија
Возраст 18 и постари · Сите полови · Ажурирано 5.8.2026 · NCT07237516Comparing Over the Counter Pain Medicines for Discomfort in Crohn's Disease (AVID-CD)
- University of North Carolina at Chapel Hill, Chapel Hill
Се регрутира
Возраст од 18 до 44 · Жени · Ажурирано 14.7.2026 · NCT07337902Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- Univ NC Chapel Hill /ID# 262198, Chapel Hill
Се регрутираФаза 3
Возраст од 2 до 17 · Сите полови · Ажурирано 24.6.2026 · NCT06332534Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Levine Children's, Charlotte
Се регрутираФаза 4
Возраст од 6 до 17 · Сите полови · Ажурирано 27.5.2026 · NCT05781152COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)
- University of North Carolina at Chapel Hill, Chapel Hill
- Atrium Health, Charlotte
- Duke Health System, Durham
Се регрутираНабљудувачка студија
Возраст од 1 до 18 · Сите полови · Ажурирано 17.4.2026 · NCT07198113A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
- Investigational Site Number: 8400003, Chapel Hill
Се регрутираФаза 2
Возраст од 18 до 75 · Сите полови · Ажурирано 27.3.2026 · NCT06958536A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, High Point
- Mirador Therapeutics Selected Site, Raleigh
Се регрутираФаза 2
Возраст од 18 до 80 · Сите полови · Ажурирано 12.3.2026 · NCT07113522Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications
- Evidera, a PPD Business Unit /ID# 238688, Morrisville
Се регрутираНабљудувачка студија
Сите возрасти · Жени · Ажурирано 17.7.2025 · NCT04846959Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.